Houston Myeloma Roundtable image

Houston Myeloma Roundtable

Oct 24, 2026
08:00AM - 02:30PM CDT
TMC3 Collaborative Building - Helix Hall
7255 Helix Park Ave, Houston, TX 77030, USA
$ 25
Overview

Join us for the Houston Myeloma Roundtable on October 24th to hear directly from leading myeloma experts about the latest in treatment and research. Designed specifically for patients and caregivers, the event includes patient-friendly presentations, breakout sessions for newly diagnosed and relapsed/refractory patients, and a dedicated faculty Q&A with plenty of time to ask questions.

Meeting Details

  • Registration & breakfast 8:00 am

  • Program: 9:00 am - 2:30 pm

  • Location: TMC3 Collaborative Building, Helix Hall

  • Breakout sessions & meals: Levy Conference Center

  • Included: Breakfast, lunch, refreshments, and parking

  • Nearest airport: George Bush Intercontinental Airport  (IAH)

Unable to attend in person? Register to receive access to the event recording.

This event will not be livestreamed. The recording will be available approximately one week after the event, and registered individuals will receive an email when it is ready.

Make it a weekend

If you are traveling to the meeting and would like to make a weekend of it while you are in Houston, here are some suggestions:

Questions?

For registration questions, contact us at  +1 800 709 1113 or email us at support@healthtree.org

To ensure we can continue providing you with excellent venues, quality meals, and a valuable experience at our Roundtable meetings, we're introducing a modest registration fee. If the fee is a financial burden, please contact us for a promotional code to waive the cost.

User uploaded media
Agenda
8:00 AM
Breakfast & Registration
9:00 AM
Welcome and Introduction
Jenny Ahlstrom
9:15 AM
Starting Strong: How Your First Myeloma Decision Shapes Your Myeloma Future
William Matsui, MD
  • Understanding today's standard treatments for newly diagnosed myeloma, including the role of stem cell transplant. 
  • How immunotherapies and emerging treatments are shaping earlier lines of care
9:45 AM
The Next Wave of Immunotherapy in Myeloma
Meera Mohan, MD, MS, FACP
  • How bispecific and trispecific antibodies work and where they fit into myeloma treatment today.
  • Using antibody-drug conjugates in myeloma care.
10:15 AM
Break
10:30 AM
CAR T-Cell Therapy for Myeloma: Who, When, and What to Expect
Krina Patel, MD, MSc
  • Who may be eligible for CAR T-cell therapy, and when it may be considered
  • What patients can expect before, during, and after treatment.
11:00 AM
HealthTree Cure Hub
Jenny Ahlstrom
11:15 AM
Breakout Sessions

Newly Diagnosed - Living Well Through Treatment: Managing Side Effects and Supportive Care, Michelly De Castro, DNP, AOCNP

OR

Relapsed Refractory - Defining "Cure" in Myeloma: What Does It Mean Today?, Meera Mohan, MD

12:00 PM
Lunch
1:00 PM
Using All the Tools in the Myeloma Toolbox: Personalizing Treatment for Every Patient
Sarvari Yellapragada, MD
  • How MRD, genetics, and individual patient factors help guide personalized treatment decisions.
  • Using today’s expanding myeloma toolbox to build the right treatment strategy over time.
1:30 PM
Round Table Audience Q&A with Faculty

  • William Matsui, MD

  • Meera Mohan,MD

  • Krina Patel, MD

  • Michelly De Castro, DNP, AOCNP

  • Sarvari V. Yellapragada, MD

2:15 PM
Help with HealthTree
Speakers & Moderators
Healthtree contact Jenny Ahlstrom

Jenny Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Healthtree contact Krina Patel, MD, MSc

Krina Patel, MD, MSc

Krina Patel, MD, MSc, is Associate Professor and Center Medical Director in the Department of Lymphoma/Myeloma of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, TX. She treats only patients with plasma cell dyscrasias and is Principal Investigator for multiple ongoing phase I/II and III immune-oncology and maintenance clinical trials for myeloma patients. Her research interests include myeloma, developing cellular therapies like CAR T, and combining immunotherapy and chemotherapy in the induction, transplant, maintenance and salvage settings and she has completed significant clinical research in hematopoeitic stem cell transplantation. Dr. Patel completed her Hematology Oncology fellowship at MDACC and served as Chief Fellow. She received her MSc for a translational project she completed in the laboratory of Dr. Laurence Cooper, evaluating the combination of CAR T cells and TCR engineered cells with vaccine in in vitro and in vivo myeloma models. She served her clinical residency in internal medicine at the University of Texas UT Health in Houston, TX and earned her medical degree at the University of Texas Southwestern Medical Center in Dallas, TX.
Healthtree contact Meera Mohan, MD, MS, FACP

Meera Mohan, MD, MS, FACP

Dr. Mohan completed her fellowship in Hematology Oncology training at the University of Arkansas for Medical Science. She has also worked and trained with some of the leading myeloma experts at the prestigious Myeloma Institute of Research and Therapeutics with in the University of Arkansas. She has authored and co-authored several peer reviewed publication and presented at various national and international conferences. During her fellowship she was awarded the Fellow’s Career Development Grant, Conquer Cancer American Society of Clinical Oncology (ASCO) Annual meeting merit award and Journal of Oncology Practice American Society of Oncology (ASCO) Editorial Fellowship. She received her Master’s in clinical and translational medicine (MS) from the University of Arkansas and served as a chief fellow. Her primary focus is to design and conduct clinical trials geared towards improving outcomes in Multiple Myeloma.
Healthtree contact William Matsui, MD

William Matsui, MD

William Matsui, MD is a Professor in the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center, where he specializes in the treatment of multiple myeloma and other plasma cell disorders. An internationally recognized physician-scientist, Dr. Matsui has spent more than two decades advancing myeloma research, with a particular focus on cancer stem cells, disease relapse, and the development of innovative immunotherapies. His clinical and research interests include stem cell transplantation, novel treatment strategies, and improving long-term outcomes for patients with multiple myeloma. He has authored more than 200 scientific publications and is a frequent speaker at national and international meetings
Healthtree contact Sarvari Yellapragada, MD

Sarvari Yellapragada, MD

Sarvari Yellapragada, MD is a Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, where she specializes in the treatment of multiple myeloma and other plasma cell disorders. She has extensive experience caring for patients across the spectrum of myeloma, with a focus on personalized treatment strategies, novel therapies, and improving long-term patient outcomes. Dr. Yellapragada is actively involved in clinical research evaluating emerging therapies and expanding access to innovative treatment approaches for patients with multiple myeloma.
Healthtree contact Michelly De Castro, DNP, APRN, AGNP-C

Michelly De Castro, DNP, APRN, AGNP-C

is a Nurse Practitioner and clinical researcher specializing in hematologic malignancies, with expertise in multiple myeloma, cellular therapies, and clinical trials. She has more than a decade of experience in oncology, including bone marrow transplantation, CAR T-cell therapy, and immunotherapy. At The University of Texas MD Anderson Cancer Center, she manages clinical research studies, collaborates with multidisciplinary teams and industry sponsors, and provides direct patient care. She is also an author of peer-reviewed research articles and book chapters in hematologic malignancies. She is passionate about advancing evidence-based practice through research and educating patients, caregivers, and healthcare professionals to improve cancer care.